Skip to content
Search

Latest Stories

Beware of cancer symptoms: NNFY scheme now available to all UK pharmacies

Beware of cancer symptoms: NNFY scheme now available to all UK pharmacies

As part of the programme, pharmacy teams are trained to spot potential early cancer symptoms in patients who visit their pharmacy 

Following the successful launch across the Alphega pharmacy network, Alliance Healthcare has decided to expand the ‘Not Normal for You?’ (NNFY) scheme to all pharmacies across the UK.

The scheme, which enables pharmacists to refer patients showing potential cancer symptoms to their GPs, has helped reveal several cases of cancer since it was rolled out in October 2023.


More than 1,000 Alphega pharmacies participated in the initial launch, with Jackie Lewis, owner of Lewis Pharmacy in Exmouth, leading the way.

Lewis explained that the NNFY scheme provides pharmacists and their staff with resources and training to detect cancer early in patients who visit their pharmacy.

After receiving £10,000 in funding from the National Pharmacy Association’s (NPA’s) Health Education Forum, Lewis first introduced the scheme to 10 pharmacies throughout East Devon. An additional grant from Bristol Myers Squibb supported in material development, upscale, and successful roll out of the project.

During the pilot phase, a patient who repeatedly purchased cough medicine in one pharmacy was referred to his GP, leading to a diagnosis of lung cancer. Six months later, the patient’s wife visited the pharmacy to thank the pharmacist as her husband was now in remission due to the early referral. The pilot also identified several cases of skin cancer.

“The timely detection of cancer is incredibly important,” Lewis said, encouraging pharmacies across the UK to participate in the scheme.

“By equipping frontline healthcare providers with the tools to recognise potential symptoms, lives can be saved through early treatment,” she added.

Jackie has developed a free online training programme called: ‘Let’s communicate cancer’ designed to educate pharmacy teams about cancer symptoms using videos and quizzes. The resource is now available on both the British Oncology Pharmacy Association and the NPA’s websites.

Dr Mandeep Mudhar, head of Alphega Pharmacy UK, highlighted that the NNFY scheme has been positively received by its members, with a growing level of engagement.

“We will continue to encourage our members and pharmacies to offer this service to their patients as part of our ambition to create healthier futures for all,”  he said.

According to Alliance Healthcare, participating pharmacies would be provided with marketing materials, such as leaflets and referral cards, free-of-charge, as part of their standard delivery.

Training would be provided to all pharmacy staff, from counter assistants to pharmacists, to enable them to spot ‘red flag’ symptoms and behaviour indicative of certain cancers.

Upon identifying symptoms, a pharmacist can discuss the issue with the individual and advise them to consult their GP if deemed necessary.

Symptoms are listed on the back of an eye-catching 'Not Normal for You?' orange referral card, which can be provided to a GP for confirmation.  While this card doesn't enable a faster GP visit, it serves as symptom validation, potentially streamlining the referral process for doctors.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less